Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9200428 | 0.85 | KMT2A (0.59) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL27281106 | 0.84 | ALDH1A1 (0.62) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL18546466 | 0.84 | ALDH1A1 (0.62) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL15743809 | 0.84 | KMT2A (0.57) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL18906021 | 0.84 | KMT2A (0.61) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL21041221 | 0.82 | KMT2A (0.68) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL8338185 | 0.82 | KMT2A (0.56) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL22236499 | 0.82 | SMN1; SMN2 (0.57) | KMT2AALDH1A1RAB9AHPGDHSD17B10 | |
| SCHEMBL3808259 | 0.81 | SMN1; SMN2 (0.57) | KMT2AALDH1A1TP53LMNAGAA | |
| SCHEMBL19460314 | 0.81 | CES2 (0.59) | KMT2AALDH1A1TP53LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707952-B | Thiadiazolidinone derivative with PTPN2/PTPN1 inhibitory activity, and preparation method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119707952-A | Thiadiazolidinone derivative with PTPN2/PTPN1 inhibitory activity, and preparation method and application thereof | 中国药科大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4053110-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083246-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2021-05-06 | — | — | WO | disclosed |
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2020-04-02 | — | — | US | disclosed |
| WO-2019101195-A1 | YEATS INHIBITORS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (CN) | 2019-05-31 | — | — | WO | disclosed |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-07 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20070232636-A1 | Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232636-A1 | Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
| US-7223789-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-29 | — | — | US | disclosed |
| US-7223789-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-29 | — | — | US | disclosed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-05-10 | — | — | US | disclosed |
| EP-1005463-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-5994396-A | Furansulfonic acid derivatives and pharmaceutical compositions containing the same | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999009022-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | KMT2A 1638/4885ALDH1A1 1440/4885TP53 3795/4885 |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | KMT2A 2483/4885ALDH1A1 2360/4885TP53 3172/4885 |
| US-20070105854-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | KMT2A 3927/4885ALDH1A1 636/4885TP53 3655/4885 |
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | KMT2A 3694/4885ALDH1A1 2830/4885TP53 183/4885 |
| US-20070105855-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDE4A, PDE4B, PDE12 | KMT2A 3927/4885ALDH1A1 636/4885TP53 3655/4885 |
| US-20070232636-A1 | Substituted Diaza-Spiro-[5.5]-Undecane Derivaties and Their Use as Neurokinin Antagonists | NPSR1, PROKR2, KISS1R | KMT2A 1426/4885ALDH1A1 700/4885TP53 4611/4885 |
| US-20230002364-A1 | BENZOTHIOPHENE DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | GPER1, GABRQ, GPR39 | KMT2A 3242/4885ALDH1A1 3177/4885TP53 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.